Myriad Genetics, Inc.

NASDAQ:MYGN

Medical - Diagnostics & Research

Healthcare
$5.53 +3.20%

+$0.14 today

Market cap
$530.45M
Beta
1.64
P/E (TTM)
-1.1
EPS (TTM)
-$4.27
52W Low $3.53High $8.59

Volume 1.26M

Average 1.81M

MYGN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Myriad Genetics, Inc.NASDAQ: MYGN

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 68.7%

Gross margin was 68.7% in Q1 FY2026, up 0.2 pp from a year earlier. On a trailing-twelve-month basis it was 70.0%, down 0.0 pp year over year. Over 3 fiscal years it narrowed by 0.3 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
68.7%-1.3 pp QoQ
Last fiscal yearDec 2025
69.9%+0.0 pp YoY
LTMMar 2026
70.0%-0.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.2 pp——
1 year+0.0 pp——
3 years-0.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
69.9%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How MYGN compares with its peers on the latest reported figures

  • MYGN's LTM Mar 2026 gross margin of 70.0% is the 3rd highest of the 10 companies compared; the peer median is 61.8%.
  • Its year-over-year change of -0.0 pp is the 5th highest of 10, against a peer median of -0.1 pp.
  • Over three fiscal years its change of -0.3 pp compares with a peer median of +2.0 pp.
MYGN Competitors Peer median
Gross Margin for MYGN and competitors
Company Period LTM level YoY 3-year change
VCYTVeracyte, Inc.LTM Jun 202672.1% +3.8 pp+3.9 pp
BLLNBillionToOne, Inc.LTM Jun 202671.3% +10.3 pp—
MYGNMyriad Genetics, Inc.LTM Mar 202670.0% -0.0 pp-0.3 pp
NTRANatera, Inc.LTM Jun 202665.3% +2.4 pp+20.5 pp
GHGuardant Health, Inc.LTM Sep 202665.2% +1.4 pp-0.8 pp
QGENQiagen N.V.LTM Jun 202661.8% -1.1 pp-2.9 pp
NEONeoGenomics, Inc.LTM Jun 202642.9% -1.0 pp+2.0 pp
FLGTFulgent Genetics, Inc.LTM Mar 202638.7% -0.1 pp-18.7 pp
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202619.5% -33.1 pp+6.6 pp
PSNLPersonalis, Inc.LTM Mar 202613.7% -19.6 pp—
Peer median (excluding MYGN) 61.8%-0.1 pp+2.0 pp

Competitors are the stored peer set for MYGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue690.6M678.4M753.2M837.6M824.5M
Cost of Revenue197.6M202M236.2M252.2M247.9M
Gross Profit493M476.4M517M585.4M576.6M
Gross Margin71.4%70.2%68.6%69.9%69.9%
Research & Development81.9M85.4M88.7M113.4M106.8M
Selling, General & Admin537.8M514.7M572.9M560M537.6M
Operating Expenses683.5M617M774.4M708.9M644.4M
Depreciation & Amortization62.8M52.7M61.9M61.2M53.7M
EBITDA12.3M(84.7M)(197.4M)(59.5M)(330.9M)
EBITDA Margin1.8%-12.5%-26.2%-7.1%-40.1%
Operating Income(190.5M)(140.6M)(257.4M)(123.5M)(67.8M)
Operating Margin-27.6%-20.7%-34.2%-14.7%-8.2%
Interest Income700K2.6M2.5M1.7M1.8M
Interest Expense6.6M3.2M2.9M2.8M10.5M
Other Income / Expenses133.4M(16.9M)(4.8M)(35.5M)(327.3M)
Income Before Tax(57.1M)(140.6M)(262.2M)(123.5M)(395.1M)
Pre-Tax Margin-8.3%-20.7%-34.8%-14.7%-47.9%
Income Tax Expense(29.9M)(28.6M)1.1M3.8M(29.2M)
Net Income(27.2M)(112M)(263.3M)(127.3M)(365.9M)
Net Margin-3.9%-16.5%-35.0%-15.2%-44.4%
EPS (Basic)(0.35)(1.39)(3.18)(1.41)(3.96)
EPS (Diluted)(0.35)(1.39)(3.18)(1.41)(3.96)
Weighted Avg Shares77.71M80.58M82.8M90.6M93.3M
Weighted Avg Shares (Diluted)78M80.6M82.8M90.6M93.3M

Myriad Genetics, Inc.

NASDAQ:MYGN

Intrinsic Alpha fair value

Locked

Current Price

$5.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.